ReviewCureus2026
Research Progress on Chronic Granulomatous Disease in Children.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic granulomatous disease (CGD) is a rare primary immunodeficiency disorder characterized by defective neutrophil oxidative burst function, leading to impaired host defense against pathogenic microorganisms. This condition significantly increases the risk of invasive infections in affected patients. However, the clinical manifestations of CGD are not limited to infection-related complications; non-infectious complications can also lead to a variety of clinical symptoms. The global occurrence rate of CGD varies, and its inheritance patterns include X-linked and autosomal recessive forms. Research indicates that CGD patients are predominantly children who frequently face life-threatening infections and related complications, with early diagnosis often being challenging. Currently, hematopoietic stem cell transplantation (HSCT) is the only widely applied curative treatment for CGD. Recent advances in gene therapy offer a promising, safer, and more directly suitable alternative. This review primarily focuses on the pathophysiology, molecular genetics, occurrence rate, clinical manifestations, laboratory diagnosis, and cellular therapies of pediatric CGD, aiming to offer ideas for its clinical diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.